Pomalidomide, Cyclophosphamide, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: Real-World Analysis of the Pethema-GEM Experience-Reference-Cited by-同舟云学术

Pomalidomide, Cyclophosphamide, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: Real-World Analysis of the Pethema-GEM Experience

Published:2021-06 Issue:6 Volume:21 Page:413-420
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Rodriguez-Otero Paula^ORCID,Sirvent Maialen^ORCID,González-Rodríguez Ana Pilar,Lavilla Esperanza^ORCID,de Coca Alfonso García,Arguiñano José María,Martí Josep M.,Cabañas Valentin,Motlló Cristina,de Cabo Erik^ORCID,Encinas Cristina,Murillo Ilda^ORCID,Hernández-Rivas Jose Ángel,Pérez-Persona Ernesto,Casado Felipe,Sampol Antonia^ORCID,García Ricarda,Blanchard María Jesús,Anguita Magdalena,Lafuente Ana Paz,Iñigo Belén,López Aurelio,Ribas Paz,Arnao Mario^ORCID,Maldonado Roberto,Bladé Joan,Mateos María Victoria,Lahuerta Juan José,San Miguel Jesús F.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference18 articles.

1. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study;Kumar;Leukemia,2012

2. Efficacy and safety of daratumumab, bortezomib, and dexamethasone (D-Vd) versus bortezomib and dexamethasone (Vd) in first relapse patients (pts) with multiple myeloma (MM): four-year update of castor;Weisel;Blood,2019

3. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial;Richardson;Lancet Oncol,2019

4. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide;Lopez-Girona;Leukemia,2012

5. Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets;Sehgal;Blood,2015

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Open-labeled, multicenter phase II study of prophylactic administration of pegylated granulocyte colony-stimulating factor in relapsed or refractory multiple myeloma who received pomalidomide-based regimens (KMM170);Frontiers in Oncology;2023-10-25

2. A phase 2 clinical trial of combined BRAF/MEK inhibition for BRAFV600E-mutated multiple myeloma;Blood;2023-04-06

3. Management of Relapsed–Refractory Multiple Myeloma in the Era of Advanced Therapies: Evidence-Based Recommendations for Routine Clinical Practice;Cancers;2023-04-05

4. Bortezomib-thalidomide-dexamethasone-cisplatin-doxorubicin-cyclophosphamide-etoposide as a Salvage and Bridging Regimen before Hematopoietic Stem Cell Transplantation for Relapsed or Refractory Multiple Myeloma;Internal Medicine;2022-11-15

5. Pomalidomide Treatment in Relapsed/Refractory Multiple Myeloma Patients—Real-World Data From Hungary;Pathology and Oncology Research;2022-10-03